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Sepsis is a systemic infl  ammatory syndrome that 
can lead to lethal organ damage. Despite ad-
vances in modern intensive care, the overall 
mortality of severe sepsis exceeds 30%, with an-
nual health care costs estimated at $16.7 billion 
in the United States (1). It is the third leading 
cause of death after cardiovascular disease and 
cancer. Death from severe sepsis occurs because 
organs become dysfunctional, especially the 
lung, liver, and kidney (2–4). Recent studies of 
the pathophysiology of organ failure in sepsis 
have implicated apoptosis (5–7). During nor-
mal embryonic development and in physiolog-
ical cell turnover in tissues, apoptotic cells are 
eliminated by phagocytes via a mechanism that 
does not activate an infl  ammatory  response. 
During severe sepsis in animals and humans, 
however, apoptotic lymphocytes accumulate in 
the spleen and thymus (5–7). It has been pro-
posed that these apoptotic lymphocytes under-
lie, at least in part, the pathogenesis of organ 
damage in severe sepsis. Administration of ex-
perimental agents that block apoptosis (e.g., 
caspase inhibitors) reduces the lethality of se-
vere sepsis in animals (5, 8), but the mechanism 
linking organ failure and death to apoptosis in 
severe sepsis was previously unknown.
Recent evidence indicates that high mobility 
group box 1 (HMGB1), a ubiquitous nuclear 
protein, is a cytokine that mediates organ damage 
in severe sepsis (9, 10). High levels of HMGB1 
accumulate in animals and humans with severe 
sepsis (9, 10). Administration of HMGB1 to 
experimental animals causes lethal organ   damage 
via a mechanism that is dependent on the 
  development of epithelial cell dysfunction (9, 11). 
Passive immunization with neutralizing anti-
HMGB1 antibodies prevents organ damage and 
epithelial dysfunction in mice subjected to severe 
sepsis (10, 11). Together, these observations 
  establish HMGB1 as a necessary and suffi   cient 
mediator of organ damage in severe sepsis. In this 
study, we show that apoptotic cells stimulate 
macrophages to release HMGB1, an event that 
is proximal in mediating the development of 
organ damage in severe sepsis.
RESULTS AND DISCUSSION
We fi  rst examined the eff  ects of caspase inhibi-
tors on bacterial endotoxin-induced HMGB1
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pathway to organ damage in severe sepsis.
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release in mouse macrophage-like RAW 264.7 cells. Z-VAD-
FMK (benzyloxycarbonyl-Val-Ala-Asp-fl  uoromethylketone), 
a broad-spectrum caspase inhibitor, concentration-depend-
ently inhibited HMGB1 release from LPS-stimulated cul-
tures as compared with the control peptide Z-FA-FMK 
(benzyloxycarbonyl-Phe-Ala-fl  uoromethylketone).  Similarly, 
Z-VAD-FMK signifi  cantly reduced the LPS-induced release 
of TNF and IL-6 (Fig. 1 A). Z-VAD-FMK decreased the 
nuclear translocation of NF-κB, which is in agreement with 
a previously described NF-κB–dependent mechanism that 
regulates LPS-induced HMGB1 release (Fig. 1 B; reference 12). 
We next subjected mice to severe sepsis in a standardized 
model of cecal ligation and puncture (CLP; reference 10). 
Animals received either Z-VAD-FMK or control peptide 
(Z-FA-FMK). Consistent with a previous study (5), Z-VAD-
FMK substantially prevented the accumulation of apop-
totic cells in the spleen and thymus, as measured by nuclear 
DNA condensation and fragmentation using terminal de-
oxynucleotidyl transferase–mediated dUTP nick end labeling 
(TUNEL) assay and caspase 3 staining (unpublished data). 
Figure 1.  Caspase inhibitor Z-VAD-FMK reduces LPS-induced cyto-
kine release, HMGB1 translocation, and NF-𝗋B activation in RAW 
264.7 cells and reduces sepsis-induced serum cytokine levels in mice. 
(A) Mouse macrophage-like RAW 264.7 cells were stimulated with 200 ng/ml 
LPS in the presence of Z-VAD-FMK or control peptide (Z-FA-FMK) at doses 
indicated for 16 h. Levels of HMGB1, TNF, and IL-6 in conditioned media 
were measured, and data are expressed as percentages of stimulation by 
LPS alone. *, P < 0.05 versus LPS + control group; n = 7. (B) RAW 264.7 
cells were stimulated with 100 ng/ml LPS in the presence of 1 or 
10 μM Z-VAD-FMK or control peptide for 6 h at 37°C. Nuclear extracts were 
prepared, and EMSA was performed using biotin-labeled nucleotides to 
measure NF-κB content. *, P < 0.05 versus LPS alone; n = 5–7 experiments. 
(C) BALB/c mice underwent CLP and received either Z-VAD-FMK or control 
peptide (0.5 mg/mouse) injected intraperitoneally at 90 min and 12 h after 
CLP. Mice were killed 24 h after CLP surgery. Serum levels of HMGB1, IL-6, 
KC, and MIP-2 were measured. *, P < 0.05 versus CLP group; n = 7–11 
mice per group. Error bars represent SEM. (D) RAW 264.7 cells were incu-
bated with 100 ng/ml LPS alone or in the presence of 1 μm Z-VAD-FMK or 
control peptide for 16 h. Cells were then incubated with polyclonal anti-
HMGB1 antibodies followed by FITC-labeled anti–rabbit antibodies and 
viewed by fl  uorescent confocal microscopy. Note that LPS caused the export 
of HMGB1 into the cytosol, whereas Z-VAD-FMK (but not control peptide) 
prevented its cytoplasmic translocation and preserved HMGB1 in the 
  nucleus. Data are representative of four separate experiments.JEM VOL. 203, July 10, 2006  1639
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Furthermore, it signifi   cantly attenuated the sepsis-induced 
systemic accumulation of HMGB1, IL-6, keratinocyte-de-
rived chemokine (KC), and macrophage infl  ammatory pro-
tein 2 (MIP-2; Fig. 1 C). Z-VAD-FMK eff  ectively blocked 
the translocation of HMGB1 from the cellular nucleus to 
the cytoplasm (Fig. 1 D). Collectively, these data indicate 
that Z-VAD-FMK attenuates HMGB1 release by decreasing 
the NF-κB–dependent translocation of HMGB1 from the 
nucleus to the cytosol.
Exposure of apoptotic cells to macrophage cultures stim-
ulates the release of HMGB1 in a dose-dependent manner. 
Similarly, exposure of macrophages to apoptotic cells also in-
duced a small but signifi  cant release of TNF and MIP-2 from 
macrophages (Fig. 2 A). HMGB1 release was observed after 
the exposure of macrophages to both apoptotic T cells (un-
published data) and apoptotic macrophages. In agreement 
with a previous study (12), necrotic cell debris also stimulated 
HMGB1 release (Fig. 2 A). Z-VAD-FMK inhibited apop-
totic cell-induced HMGB1 release (Fig. 2 B), indicating that 
the accumulation of apoptotic cells can activate macrophages 
to release HMGB1 and other proinfl  ammatory cytokines.
To determine whether inhibiting HMGB1 attenuates 
the accumulation of apoptotic cells, we administered neu-
tralizing anti-HMGB1 mAbs (Fig. 3 A) to mice with severe 
sepsis. Dose-response experiments revealed that treatment 
with anti-HMGB1 mAb signifi  cantly reduced sepsis lethality 
(Fig. 3 A). As shown in Fig. 3 B, serum levels of lactate de-
hydrogenase (LDH), blood urea nitrogen (BUN), alkaline 
phosphatase, serum glutamate pyruvate transaminase (SGPT), 
and serum glutamate oxaloacetate transaminase (SGOT) 
were all elevated in severe sepsis and signifi  cantly reduced by 
treatment with anti-HMGB1 mAb as compared with con-
trols receiving non  immune IgG. Spleen bacterial counts 
were not signifi  cantly diff  erent between treatment groups 
(unpublished data). Anti-HMGB1 mAb also signifi  cantly re-
duced serum levels of proinfl  ammatory cytokines and che-
mokines, including IL-6, KC, and MIP-1α but not the 
anti-infl   ammatory cytokine IL-10 (Fig. 3 C). Together, 
these experimental data suggest that anti-HMGB1 mAb 
confers protection against severe sepsis by preventing the 
  development of organ damage.
TUNEL assay, caspase 3, and Annexin VI staining re-
vealed that apoptotic cells accumulated in the spleen of mice 
with severe sepsis (Fig. 4 A, top). No apparent apoptosis was 
observed in the kidney of these mice (unpublished data). 
Even though the administration of anti-HMGB1 mAb did 
not alter apoptosis in the spleen, HMGB1 mAb reduced 
  sepsis-induced focal apoptosis in the liver (Fig. 4 A, bottom). 
Pathological evaluation revealed sepsis-induced lung injury 
with alveolar septal thickening, cellular infi  ltrates, alveolar 
congestion, hemorrhage, and edema in septic mice.  Treatment 
with anti-HMGB1 mAb substantially decreased the severity 
of acute lung injury (Fig. 4 B). Sepsis-induced liver injury 
(focal necrosis and infl  ammation) was also reduced by the 
  administration of anti-HMGB1 mAb (Fig. 4 B). No apparent 
diff   erences were observed in tissue sections obtained 
from anti-HMGB1 mAb and IgG treatment groups in the 
kidney (Fig. 4 B), heart, and small intestine (not depicted). 
Figure 2.  Necrotic and apoptotic cells induce HMGB1, TNF, and 
MIP-2 release in RAW 264.7 cells; Z-VAD-FMK inhibits apoptotic 
cell-induced HMGB1 release. (A) Normal, apoptotic, or necrotic cells 
were added to RAW 264.7 cells at the amounts indicated for 16 h at 37°C. 
HMGB1, TNF, and MIP-2 released in conditioned media were measured. 
*, P < 0.05 versus normal control group; n = 6–8 independent experiments. 
(B) Apoptotic cells were added to RAW 264.7 cells at the amounts 
  indicated in the presence of 10 μM Z-VAD-FMK or control peptide for 
16 h at 37°C, and the HMGB1 released was measured by Western blotting 
(9, 10). *, P < 0.05 versus apoptotic cells alone; n = 6–8 independent 
experiments. Error bars represent SEM.1640  ROLE OF HMGB1 IN APOPTOSIS-MEDIATED SEPSIS LETHALITY | Qin et al.
Figure 4.  Anti-HMGB1 mAb reduces serum levels of proinfl  amma-
tory cytokines and organ damage without altering apoptosis in the 
spleen of septic mice. BALB/c mice were subjected to CLP surgery and 
received anti-HMGB1 mAb or nonimmune IgG administered intraperitone-
ally at 10 μg/mouse 24 h after CLP. Mice were killed 40 h after CLP surgery. 
In some experiments, between 30 and 72 h after CLP, any mice that looked 
very ill were killed (another mouse was killed from the control group at 
the same time). (A) Tissue sections of spleens (top) and livers (bottom) of 
  normal or septic mice were prepared by using the standard formalin-fi  xed, 
paraffi  n-embedded procedure and were mounted on glass slides, and 
  TUNEL assay, caspase 3 (top), and Annexin VI (top) stainings were performed. 
Arrows indicate the positive-staining cells. (B) Tissues were stained with 
hematoxylin and eosin. (top left) Normal lung shows thin alveolar septal 
wall and normal cellularity. (top middle) Lung from a septic mouse showing 
alveolar septal wall thickening, increase in cellular infi  ltrates, alveolar con-
gestion, hemorrhage, and edema (arrow). (top right) Lung from a septic 
mouse treated with anti-HMGB1 mAb showing near normal alveoli with 
thin septum. (middle left) Normal liver showing a central vein (arrow) 
  surrounded by hepatocytes and sinusoids. (middle) Liver from a septic 
mouse showing a congested central vein (arrow) and necrotic lesions 
  (arrows) as revealed by the loss of cells and the structure of hepatic acinus. 
(middle right) Liver from a septic mouse treated with anti-HMGB1 mAb 
showing a central vein (arrow) and surrounding near normal hepatocytes. 
(bottom left) Normal kidney showing cortex with the glomerulus (G). 
(bottom middle) Kidney from a septic mouse showing the cortex with swell-
ing tubule epithelia and congestion. (bottom right) Kidney from a septic 
mouse treated with anti-HMGB1 mAb showing swelling tubule epithelia 
and   congestion. Data are representative of four to eight animals per group. 
Figure 3.  Treatment with anti-HMGB1 mAb increases survival and 
reduces serum levels of cytokines and enzymes in sepsis induced by 
CLP. (A) BALB/c mice were subjected to CLP surgery (n = 10–22 mice per 
group). At 24 h after CLP surgery, mice received a single dose of anti-
HMGB1 mAb at 0.1, 1, or 10 μg/mouse or control IgG injected intraperito-
neally. No signifi  cant difference was observed in mice treated with different 
amounts of IgG (0.1, 1, or 10 μg/mouse; not depicted). Animal survival was 
monitored for 2 wk. *, P < 0.01 versus the IgG-treated group. (B and C) 
BALB/c mice had CLP surgery and received anti-HMGB1 mAb or nonim-
mune IgG administered intraperitoneally at 10 μg per mouse 24 h after 
CLP and were killed 40 h after surgery. (B) Serum levels of LDH, BUN, alka-
line phosphatase (Alk Phos), SGPT, and SGOT were measured using com-
mercially obtained assay kits. (C) Serum levels of IL-6, KC, MIP-1α, and 
IL-10 were measured by ELISAs, and HMGB1 was measured. Data are 
means ± SEM (error bars) of 5–13 animals in each group. *, P < 0.05 
  versus CLP group.JEM VOL. 203, July 10, 2006  1641
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Collectively, our data suggest that anti-HMGB1 mAb im-
proves survival in severe sepsis by preventing vital organ 
damage in lungs and livers without altering the development 
of sepsis-induced apoptosis in the spleen.
These results provide evidence that administration of 
the caspase inhibitor Z-VAD-FMK considerably decreases 
HMGB1 release from macrophages and decreases serum 
HMGB1 levels in mice with severe sepsis. The relationships 
between HMGB1 and apoptosis are complex. A previous 
study demonstrated that HMGB1 can be passively released 
by necrotic cells, thereby transmitting the “injury” signal to 
neighboring immune cells (12). However, HMGB1 is not 
released by apoptotic cells, which dissolve without setting off   
an infl  ammatory response. Our experimental data indicate 
that exposure of macrophages to apoptotic cells activates 
HMGB1 release. Accordingly, it appears that the excessive 
accumulation of apoptotic cells in severe sepsis can activate 
a downstream release of HMGB1, which mediates organ 
damage (Fig. 5).
Other work has indicated that HMGB1 acts as an in-
hibitor of apoptosis and as a pro-oncogene in tumorigenesis 
(13–15). Increased HMGB1 levels are observed in colon 
tumors and are associated with enhanced levels of anti-
apoptotic protein c-IAP2 (13). High levels of HMGB1 are 
also observed in human primary breast carcinoma and in 
experimental sepsis, endotoxemia, arthritis, and hepatic 
ischemia reperfusion injury (16–20). HMGB1 levels are in-
creased in human sepsis (9). Previous studies showed that 
HMGB1 can be passively released by necrotic or damaged 
cells and actively secreted by macrophages/monocytes and 
dendritic cells upon stimulation (9, 12, 21). We have now 
discovered that apoptotic cells can stimulate HMGB1 re-
lease by macrophages in animals with severe sepsis. HMGB1 
is downstream of apoptosis on the fi  nal common pathway 
to organ damage.
We previously showed that polyclonal anti-HMGB1 
  antibodies protect against sepsis lethality (10). In this study, 
we used HMGB1-specifi  c monoclonal antibodies in a sin-
gle dose of 10 μg per mouse (0.4 mg/kg) to increase sur-
vival in sepsis, indicating a previously unrecognized potency 
and specifi  city of anti-HMGB1 treatment in sepsis.  Although 
it had been generally accepted that the clearance of apop-
totic cells is via a noninfl  ammatory pathway, it now appears 
that the accumulation of apoptotic cells may provoke other 
cells to release HMGB1, which, in turn, mediates severe 
organ damage.
MATERIALS AND METHODS
Reagents. 10% neutral formalin solution, FITC-labeled anti–rabbit IgG, 
LPS (Escherichia coli; 0111:B4), and camptothecin were obtained from Sigma-
Aldrich. Polycaspase inhibitor Z-VAD-FMK and control peptide Z-FA-FMK 
were obtained from BD Biosciences. Anticaspase 3 antibodies were  purchased 
from R&D Systems. Recombinant rat HMGB1 was isolated, and contami-
nating LPS was removed as previously described (10, 22). LPS content is 
<0.1 ng/μg of protein (22).
Generation of neutralizing mAbs to HMGB1 and epitope mapping. 
Female BALB/c mice (5–6 wk old) were immunized with recombinant 
HMGB1 mixed with Freund’s adjuvant injected intraperitoneally, and a fi  nal 
boost was given intravenously. Mice were killed after the fi  nal boost, and 
spleen cells were fused with myeloma cells according to a standard protocol. 
For epitope mapping, overlapping 18–amino acid peptides covering the 
  entire HMGB1 sequence were synthesized by BioSource International. 
Neutralizing activity of anti-HMGB1 mAbs was assessed in macrophage cul-
tures exposed to HMGB1 and assayed for the ability to inhibit TNF release 
(10). Clone 1 was found to bind a region between amino acids 53 and 63, 
and clone 2 bound to amino acids 67–78 of the protein, both in the A box 
region of HMGB1. Both clones were tested in the animal experiments.
Cell culture. Mouse macrophage-like RAW 264.7 cells (American Type 
Culture Collection) were cultured as previously described (10). Apoptosis 
was induced by treating the cells with 6 μM camptothecin at 37°C for 4 h. 
Necrosis was induced by three cycles of freezing and thawing. Cells were 
confi  rmed to be apoptotic by caspase 3 staining. Necrosis was verifi  ed by 
microscopic evaluation showing cell fragments but no intact cells.
EMSA for NF-𝗋B activation. RAW 264.7 cells were stimulated with 
100 ng/ml LPS alone or in the presence of 1 or 10 μM Z-VAD-FMK or 
control peptide Z-FA-FMK for 6 h at 37°C. Nuclear extracts were prepared, 
and electrophoretic mobility shift assay (EMSA) was performed using biotin-
  labeled oligonucleotides to measure NF-κB content (Pierce Chemical Co.).
HMGB1 staining and confocal microscopy. RAW 264.7 cells cultured 
in slide chambers were stimulated with 100 ng/ml LPS alone or in the pres-
ence of 1 μM Z-VAD-FMK or control peptide for 16 h at 37°C. Intracellu-
lar localization of HMGB1 was determined by using 2.5 μg/ml HMGB1 
antibodies followed by incubation with FITC-labeled anti–rabbit IgG. Cells 
were mounted for viewing by fl  uorescent confocal microscopy.
Animal experiments. Male 6–8-wk-old BALB/c mice (Sprague-Dawley; 
Harlan) were housed in The Feinstein Institute for Medical Research 
(FIMR) Animal Facility. All animal procedures were approved by the insti-
tute’s Institutional Animal Care and Use Committee. Mice were subjected 
to CLP procedure (10, 23), and anti-HMGB1 mAb was given intraperitone-
ally at 24 h after CLP. In parallel experiments, mice were killed at various 
time points to collect blood and tissues (lungs, livers, kidneys, hearts, small 
intestine, and spleens). Splenic bacteria were recovered as previously 
  described (10). In some experiments, mice were given caspase inhibitors 
Figure 5.  Model of the protective effects of anti-HMGB1 treat-
ment in sepsis lethality. The excessive release of HMGB1 is toxic, and it 
causes organ damage and death. Sepsis can induce cell apoptosis. Apop-
totic cells phagocytosed by macrophages release HMGB1. Caspase inhibitor 
Z-VAD-FMK inhibits both cell apoptosis and HMGB1 release directly and, 
thus, improves sepsis survival. Anti-HMGB1 mAbs improve sepsis survival 
by neutralizing HMGB1 toxicity without altering sepsis-induced apoptosis 
in the spleen.1642  ROLE OF HMGB1 IN APOPTOSIS-MEDIATED SEPSIS LETHALITY | Qin et al.
(Z-VAD-FMK) or control peptide (Z-FA-FMK; 0.5 mg/mouse injected 
intraperitoneally) at 90 min and 12 h and were killed 24 h after CLP.
Measurements of cytokine and serum enzymes. Serum levels of cytokines 
were determined by ELISA kits (R&D Systems). Serum levels of BUN, LDH, 
alkaline phosphatase, SGPT, and SGOT were measured by commercially ob-
tained assay kits. HMGB1 was measured by Western immunoblotting (9, 10).
Analyses of tissue histology and apoptosis. Immediately after killing, 
tissues were fi  xed, and sections were made and stained with hematoxylin and 
eosin for morphologic evaluations. For apoptosis analyses, TUNEL staining 
was performed by using the ApoAlert DNA fragmentation assay kit (BD 
Biosciences), and caspase 3 expression was determined by using an immuno-
staining kit (ABC kit; Vector Laboratories).
Statistical analysis. Data are presented as means ± SEM. Diff  erences be-
tween treatment groups were determined by Student’s t test and one-way 
analysis of variance followed by the least signifi  cant diff  erence test or Fisher’s 
exact test. P < 0.05 was considered statistically signifi  cant.
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